Innovative immunological and target therapies for NMIBC: Recent clinical trial data shaping the future : Episode 5
Opinion
Video
BOND-003: Clinical Implications for HR BCG-Unresponsive NMIBC Treatment
Author(s):
Gary D. Steinberg, MD explains the implications of the BOND-003 results for clinical practice in treating non-muscle-invasive bladder cancer (NMIBC), highlighting the potential benefits of novel immunotherapeutic options like cretostimogene grenadenorepvec as a bladder-sparing therapy for BCG-unresponsive high-risk NMIBC, and discusses how this treatment could fit into the NMIBC treatment landscape if approved.
Video Player is loading.
Video content above is prompted by the following questions:
- What could the results from BOND-003 mean for clinical practice in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC)?
- What type of patient could benefit from novel immunotherapeutic options (bladder sparing therapy) for BCG-unresponsive high-risk non-muscle-invasive bladder cancer?
- If approved, how does cretostimogene fit into the treatment landscape for patients with NMBIC?
Related Videos
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
John Taylor, III, MD, on novel options in NMIBC
Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
What a long-term study of patients undergoing RARC reveals about upstaging
Sima Porten, MD, on the increased risk of bladder cancer among firefighters
Jason Hafron, MD, predicts coming advancements in bladder cancer
Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
Neeraja Tillu, MD, discusses predictors of upstaging following RARC for NMIBC
Related Content
